Small Molecules

15 Jan 2019 Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
15 Jan 2019 New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
15 Jan 2019 Aslan Pharmaceuticals announces study results from phase 2 study of varlitinib in first-line gastric cancer
12 Jan 2019 ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease
12 Jan 2019 Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
09 Jan 2019 Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201
09 Jan 2019 Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
09 Jan 2019 Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
09 Jan 2019 Basilea reports positive interim results from registrational phase 2 study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma (iCCA)
09 Jan 2019 UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
08 Jan 2019 Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
08 Jan 2019 Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor
08 Jan 2019 Collaborative Medicinal Development, LLC Reports that Lead Drug Modifies ALS Progression
07 Jan 2019 Neumentum Phase I Study Confirms Its Non-Opioid in Development for Moderately Severe Acute Pain, NTM-001, Performs in Healthy Adults as Predicted
07 Jan 2019 Oppilan Pharma Initiates Phase 1 Clinical Study with OPL-002
07 Jan 2019 Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
07 Jan 2019 Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder
07 Jan 2019 Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma
07 Jan 2019 Lilly Announces Agreement To Acquire Loxo Oncology
07 Jan 2019 Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression
07 Jan 2019 Vifor Pharma receives positive phase-I trial results for oral ferroportin inhibitor
07 Jan 2019 Sosei Heptares to Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2
07 Jan 2019 Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia
07 Jan 2019 Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
07 Jan 2019 Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up